IRVINE, Calif. -- (Business Wire)

Lombard Medical, Inc. announced today the pricing of the initial public offering of 5,000,000 ordinary shares at a price to the public of $11 per share. The shares will be listed on the NASDAQ Global Market under the ticker symbol “EVAR” on April 25, 2014. In addition, Lombard Medical, Inc. has granted the underwriters a 30-day option to purchase up to an additional 750,000 ordinary shares from Lombard Medical, Inc.

In advance of Lombard Medical, Inc.'s shares commencing trading on the NASDAQ Global Market, trading in the shares of Lombard Medical Technologies PLC on the AIM market of the London Stock Exchange will be suspended and trading in the shares will be cancelled.

Jefferies LLC and Barclays Capital Inc. are acting as joint book-running managers for the proposed offering, and BTIG, LLC is acting as co-manager.

A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission.

The offering will be made only by means of a prospectus, copies of which may be obtained from Jefferies LLC, Equity Syndicate Prospectus Department, by email at Prospectus_Department@Jefferies.com, by phone at 877-547-6340 or by mail at 520 Madison Avenue, 2nd Floor, New York, NY 10022 or Barclays Capital Inc., c/o Broadridge Financial Solutions, by email at Barclaysprospectus@broadridge.com, by phone at 888-603-5847 or by mail at 1155 Long Island Avenue, Edgewood, NY 11717.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Lombard Medical, Inc.

Lombard Medical, Inc. will become the parent company of Lombard Medical Technologies PLC (“LMT”), a medical device company focused on device solutions for the $1.4 billion per annum abdominal aortic aneurysm repair market following a court approved scheme of arrangement. LMT’s lead product, Aorfix™, is an endovascular stent graft which has been specifically designed to solve the problems that exist in treating complex tortuous anatomy, which is often present in advanced AAA disease. LMT is headquartered in Oxfordshire, England with US operations in Irvine, CA. Lombard Medical, Inc. is registered in the Cayman Islands.

Contacts:

Lombard Medical, Inc.
Simon Hubbert, Chief Executive Officer
Ian Ardill, Chief Financial Officer
Tel: +1 (0) 949 379 3750
or
Lombard Medical Technologies PLC
Simon Hubbert, Chief Executive Officer
Ian Ardill, Chief Financial Officer
Tel: +44 (0)1235 750 800
or
Pure Communications (US)
Matthew H Clawson
Tel: +1 949 370 8500
matt@purecommunicationsinc.com
or
FTI Consulting (UK)
Simon Conway / Stephanie Cuthbert / Victoria Foster Mitchell
Tel: +44 (0) 203 727 1000

Source: Lombard Medical, Inc.